Alkaloids and Drug Discovery for Neurodegenerative Diseases

[1]  E. Perry,et al.  Medicinal Plants and Dementia Therapy: Herbal Hopes for Brain Aging? , 2011, CNS neuroscience & therapeutics.

[2]  A. Lang,et al.  Caffeine in Parkinson's disease: A pilot open‐label, dose‐escalation study , 2011, Movement disorders : official journal of the Movement Disorder Society.

[3]  N. Greig,et al.  Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons , 2011, PloS one.

[4]  P. Carlier,et al.  Bis(12)-hupyridone, a novel multifunctional dimer, promotes neuronal differentiation more potently than its monomeric natural analog huperzine A possibly through alpha7 nAChR , 2011, Brain Research.

[5]  Yinghe Hu,et al.  Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline. , 2011, Biochemical and biophysical research communications.

[6]  A. Kinghorn,et al.  The relevance of higher plants in lead compound discovery programs. , 2011, Journal of natural products.

[7]  P. Carlier,et al.  Preventing H2O2-induced apoptosis in cerebellar granule neurons by regulating the VEGFR-2/Akt signaling pathway using a novel dimeric antiacetylcholinesterase bis(12)-hupyridone , 2011, Brain Research.

[8]  J. Rothstein,et al.  Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression , 2011, Neuropharmacology.

[9]  E. Perry,et al.  The Role of Phytochemicals in the Treatment and Prevention of Dementia , 2011, Drugs & aging.

[10]  P. Williams,et al.  Natural products as a source of Alzheimer's drug leads. , 2011, Natural product reports.

[11]  A. Prakash,et al.  Role of vinpocetine in cerebrovascular diseases , 2011, Pharmacological reports : PR.

[12]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[13]  J. White,et al.  The structures of four new himbacine-like Galbulimima alkaloids , 2011 .

[14]  Y. Tseng,et al.  Arecoline, a major alkaloid of the areca nut, causes neurotoxicity through enhancement of oxidative stress and suppression of the antioxidant protective system. , 2010, Free radical biology & medicine.

[15]  Ming Yan,et al.  Protective effects of galantamine against Aβ-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress , 2010, Neurochemistry International.

[16]  Yan Zhang,et al.  Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells , 2010, Experimental Gerontology.

[17]  K. Takata,et al.  Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors* , 2010, The Journal of Biological Chemistry.

[18]  M. Morelli,et al.  Can dietary substances protect against Parkinson's disease? The case of caffeine , 2010, Experimental Neurology.

[19]  Dong-lai Wu,et al.  Galantamine inhibits calpain–calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells , 2010, Neuroscience Letters.

[20]  Aamir Nazir,et al.  Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology. , 2010, Journal of medicinal chemistry.

[21]  A. Nordberg,et al.  Effect of Huprine X on β-Amyloid, Synaptophysin and α7 Neuronal Nicotinic Acetylcholine Receptors in the Brain of 3xTg-AD and APPswe Transgenic Mice , 2010, Neurodegenerative Diseases.

[22]  G. Le Douaron,et al.  Tryptamine-derived alkaloids from Annonaceae exerting neurotrophin-like properties on primary dopaminergic neurons. , 2010, Bioorganic & medicinal chemistry.

[23]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[24]  M. Jung,et al.  Scopolamine-induced learning impairment reversed by physostigmine in zebrafish , 2010, Neuroscience Research.

[25]  S. Wonnacott,et al.  Increase in locomotor activity after acute administration of the nicotinic receptor agonist 3-bromocytisine in rats. , 2010, European journal of pharmacology.

[26]  C. Cao,et al.  Caffeine and coffee as therapeutics against Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[27]  N. Lunet,et al.  Caffeine exposure and the risk of Parkinson's disease: a systematic review and meta-analysis of observational studies. , 2010, Journal of Alzheimer's disease : JAD.

[28]  Xiaohua Cao,et al.  A novel derivative of xanomeline improves fear cognition in aged mice , 2010, Neuroscience Letters.

[29]  P. Mukherjee,et al.  Acetylcholinesterase enzyme inhibitory potential of standardized extract of Trigonella foenum graecum L and its constituents. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[30]  H. Kogen,et al.  Development of an efficient therapeutic agent for Alzheimer's disease: design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter. , 2010, Chemical & pharmaceutical bulletin.

[31]  R. Bartha,et al.  Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  E. Krenzelok.  Aspects of Datura poisoning and treatment , 2010, Clinical toxicology.

[33]  D. Lahiri,et al.  A novel effect of rivastigmine on pre‐synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease , 2010, Journal of neurochemistry.

[34]  John Dunlop,et al.  Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease. , 2010, Current topics in medicinal chemistry.

[35]  Taufiq Rahman,et al.  Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. , 2010, Bioorganic & medicinal chemistry letters.

[36]  S. Ostad,et al.  Cytotoxicity of Vinca minor , 2010, Pharmaceutical biology.

[37]  N. Poungvarin,et al.  Galantamine for the Treatment of BPSD in Thai Patients With Possible Alzheimer's Disease With or Without Cerebrovascular Disease , 2009, American journal of Alzheimer's disease and other dementias.

[38]  Vivek Sharma,et al.  Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor. , 2009, European journal of pharmacology.

[39]  P. Taylor,et al.  Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal α7 nicotinic acetylcholine receptor , 2009, The EMBO journal.

[40]  C. Ammer,et al.  Evolution of morphine biosynthesis in opium poppy. , 2009, Phytochemistry.

[41]  S. Varanese,et al.  Fava beans and Parkinson’s disease: useful ‘natural supplement’ or useless risk? , 2009, European journal of neurology.

[42]  J. Kaprio,et al.  Coffee drinking in middle age is not associated with cognitive performance in old age. , 2009, The American journal of clinical nutrition.

[43]  Antoine Taly,et al.  Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system , 2009, Nature Reviews Drug Discovery.

[44]  Warren M Grill,et al.  Implanted neural interfaces: biochallenges and engineered solutions. , 2009, Annual review of biomedical engineering.

[45]  B. Figadère,et al.  An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities. , 2009, Current medicinal chemistry.

[46]  Ling Yang,et al.  Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide. , 2009, Free radical biology & medicine.

[47]  Csaba Nyakas,et al.  Neuroprotective Effects of Vinpocetine and its Major Metabolite Cis‐apovincaminic Acid on NMDA‐Induced Neurotoxicity in a Rat Entorhinal Cortex Lesion Model , 2009, CNS neuroscience & therapeutics.

[48]  B. Austen,et al.  Galantamine inhibits β-amyloid aggregation and cytotoxicity , 2009, Journal of the Neurological Sciences.

[49]  M. Morelli,et al.  Assessment of Symptomatic and Neuroprotective Efficacy of Mucuna Pruriens Seed Extract in Rodent Model of Parkinson’s Disease , 2009, Neurotoxicity Research.

[50]  Hong-Zhuan Chen,et al.  Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis , 2009, Journal of Neural Transmission.

[51]  P. Agostinho,et al.  Galantamine protects against oxidative stress induced by amyloid‐beta peptide in cortical neurons , 2009, The European journal of neuroscience.

[52]  A. Akaike,et al.  Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells. , 2008, European journal of pharmacology.

[53]  I. Litvinenko,et al.  Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) , 2008, Neuroscience and Behavioral Physiology.

[54]  D. Muñoz-Torrero.  Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. , 2008, Current medicinal chemistry.

[55]  O. Abdel-Salam.  Drugs used to treat Parkinson's disease, present status and future directions. , 2008, CNS & neurological disorders drug targets.

[56]  J. P. Petzer,et al.  Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. , 2008, Bioorganic & medicinal chemistry.

[57]  S. Wonnacott,et al.  In vivo modulation of dopaminergic nigrostriatal pathways by cytisine derivatives: implications for Parkinson's Disease. , 2008, European journal of pharmacology.

[58]  R. Tundis,et al.  Natural products and their derivatives as cholinesterase inhibitors in the treatment of neurodegenerative disorders: an update. , 2008, Current medicinal chemistry.

[59]  K. Blennow,et al.  Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease , 2008, Annals of neurology.

[60]  N. Greig,et al.  Kinetics of Human Serum Butyrylcholinesterase Inhibition by a Novel Experimental Alzheimer Therapeutic, Dihydrobenzodioxepine Cymserine , 2008, Neurochemical Research.

[61]  A H V Schapira,et al.  Progress in neuroprotection in Parkinson’s disease , 2008, European journal of neurology.

[62]  C. Codina,et al.  N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. , 2008, Bioorganic & medicinal chemistry letters.

[63]  Arvind Saklani,et al.  Plant-derived compounds in clinical trials. , 2008, Drug discovery today.

[64]  K. Rangappa,et al.  Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models , 2008, Neurochemistry International.

[65]  N. Greig,et al.  Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis , 2008, Journal of Neural Transmission.

[66]  Yitao Wang,et al.  The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine. , 2008, Journal of pharmaceutical and biomedical analysis.

[67]  S. Janhunen,et al.  Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: Implications for drug development , 2007, Neuroscience & Biobehavioral Reviews.

[68]  S. Schachter,et al.  Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695 , 2007, Neuroscience.

[69]  S. Arneric,et al.  Neuronal nicotinic receptors: a perspective on two decades of drug discovery research. , 2007, Biochemical pharmacology.

[70]  Marek Bajda,et al.  Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. , 2007, Current medicinal chemistry.

[71]  T. Herraiz.  Identification and occurrence of beta-carboline alkaloids in raisins and inhibition of monoamine oxidase (MAO). , 2007, Journal of agricultural and food chemistry.

[72]  R. Hellweg,et al.  Neurotrophic factors--a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? , 2007, Current medicinal chemistry.

[73]  P. Barberger‐Gateau,et al.  The neuroprotective effects of caffeine , 2007, Neurology.

[74]  A. Valikovics.  [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. , 2007, Ideggyogyaszati szemle.

[75]  N. Greig,et al.  Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine , 2007, Proceedings of the National Academy of Sciences.

[76]  F. Pasquier,et al.  Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study , 2007, Dementia and Geriatric Cognitive Disorders.

[77]  N. Greig,et al.  The Experimental Alzheimer's Disease Drug Posiphen [(+)-Phenserine] Lowers Amyloid-β Peptide Levels in Cell Culture and Mice , 2007, Journal of Pharmacology and Experimental Therapeutics.

[78]  M. Allam,et al.  Alzheimer's disease and coffee: a quantitative review , 2007, Neurological research.

[79]  H. Zhang,et al.  Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. , 2006, Trends in pharmacological sciences.

[80]  Ana Martínez,et al.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. , 2006, Current pharmaceutical design.

[81]  D. Braida,et al.  Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. , 2006, CNS drug reviews.

[82]  T. Langer,et al.  Strategies for efficient lead structure discovery from natural products. , 2006, Current medicinal chemistry.

[83]  J. P. Petzer,et al.  Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC). , 2006, Bioorganic & Medicinal Chemistry.

[84]  I. Orhan,et al.  Recent Developments in Natural and Synthetic Drug Research for Alzheimers Disease , 2006 .

[85]  M. Sabbagh,et al.  Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? , 2006, Alzheimer's & Dementia.

[86]  P. Houghton,et al.  Acetylcholinesterase inhibitors from plants and fungi. , 2006, Natural product reports.

[87]  Shahin Akhondzadeh,et al.  Herbal medicine in the treatment of Alzheimer's disease , 2006, American journal of Alzheimer's disease and other dementias.

[88]  F. Joseph McClernon,et al.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization , 2006, Psychopharmacology.

[89]  R. N. Takahashi,et al.  Pilocarpine improves olfactory discrimination and social recognition memory deficits in 24 month-old rats. , 2006, European journal of pharmacology.

[90]  N. Greig,et al.  Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine. , 2006, Biochimica et biophysica acta.

[91]  C. Gotti,et al.  Brain neuronal nicotinic receptors as new targets for drug discovery. , 2006, Current pharmaceutical design.

[92]  L. Schneider,et al.  Galantamine for Alzheimer's disease and mild cognitive impairment. , 2006, The Cochrane database of systematic reviews.

[93]  J. Birks,et al.  Cholinesterase inhibitors for Alzheimer's disease. , 2006 .

[94]  Manuela G. López,et al.  Unequal Neuroprotection Afforded by the Acetylcholinesterase Inhibitors Galantamine, Donepezil, and Rivastigmine in SH-SY5Y Neuroblastoma Cells: Role of Nicotinic Receptors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[95]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[96]  B. Fan,et al.  Activity and QSAR study of baogongteng A and its derivatives as muscarinic agonists. , 2005, Bioorganic & medicinal chemistry letters.

[97]  N. Greig,et al.  Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. , 2005, Current Alzheimer research.

[98]  J. Clader,et al.  Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. , 2005, Current pharmaceutical design.

[99]  N. Greig,et al.  An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 2005, Current Alzheimer research.

[100]  J. Daly.  Nicotinic Agonists, Antagonists, and Modulators From Natural Sources , 2005, Cellular and Molecular Neurobiology.

[101]  P. Houghton,et al.  Natural Products and Derivatives Affecting Neurotransmission Relevant to Alzheimer’s and Parkinson’s Disease , 2005, Neurosignals.

[102]  Katsuko Komatsu,et al.  Search for Natural Products Related to Regeneration of the Neuronal Network , 2005, Neurosignals.

[103]  M. Butler.  Natural products to drugs: natural product-derived compounds in clinical trials. , 2005, Natural product reports.

[104]  A. Carobrez,et al.  Pilocarpine prevents age-related spatial learning impairments in rats , 2005, Behavioural Brain Research.

[105]  S. Arnold,et al.  A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? , 2005, Trends in pharmacological sciences.

[106]  T. Herraiz,et al.  Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. , 2005, Biochemical and biophysical research communications.

[107]  D. Gang,et al.  The Lycopodium alkaloids. , 2004, Natural product reports.

[108]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[109]  B. Pirotte,et al.  New trends in the design of drugs against Alzheimer's disease. , 2004, Current medicinal chemistry.

[110]  M. Heinrich,et al.  Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. , 2004, Journal of ethnopharmacology.

[111]  P. Herrling,et al.  List of Drugs in Development for Neurodegenerative Diseases , 2004, Neurodegenerative Diseases.

[112]  S. R. Breining.  Recent developments in the synthesis of nicotinic acetylcholine receptor ligands. , 2004, Current topics in medicinal chemistry.

[113]  Zhong Jin.  Muscarine, imidazole, oxazole, and thiazole alkaloids. , 2003, Natural product reports.

[114]  E. Levin,et al.  Lobeline-induced learning improvement of rats in the radial-arm maze , 2003, Pharmacology Biochemistry and Behavior.

[115]  P. Houghton,et al.  Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function , 2003, Pharmacology Biochemistry and Behavior.

[116]  P. Camps,et al.  Characterisation of the anticholinesterase activity of two new tacrine–huperzine A hybrids , 2003, Neuropharmacology.

[117]  S. Terashima,et al.  Synthetic studies on himbacine, a potent antagonist of the muscarinic M2 subtype receptor. Part 2: synthesis and muscarinic M2 subtype antagonistic activity of the novel himbacine congeners modified at the C-3 position of lactone moiety. , 2003, Bioorganic & medicinal chemistry.

[118]  L. Schneider,et al.  A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. , 2003, Current drug targets.

[119]  P. Whitehouse,et al.  Vinpocetine for cognitive impairment and dementia. , 2003, The Cochrane database of systematic reviews.

[120]  A. de Mendonça,et al.  Does caffeine intake protect from Alzheimer's disease? , 2002, European journal of neurology.

[121]  N. Vivas,et al.  Interaction of a new potent anticholinesterasic compound (±)huprine X with muscarinic receptors in rat brain , 2002, Neuroscience Letters.

[122]  C. Ballard,et al.  Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition , 2002, European Neurology.

[123]  N. Greig,et al.  Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. , 2001, Journal of medicinal chemistry.

[124]  J. Mulzer,et al.  Synthesis and acetylcholinesterase inhibition of 5-desamino huperzine A derivatives. , 2001, Bioorganic & medicinal chemistry letters.

[125]  M. Stubbs,et al.  Synthesis and evaluation of diazine containing bioisosteres of (-)-ferruginine as ligands for nicotinic acetylcholine receptors. , 2001, Bioorganic & medicinal chemistry.

[126]  J. Jankovic,et al.  Are Dopamine Receptor Agonists Neuroprotective in Parkinson’s Disease? , 2001, Drugs & aging.

[127]  N. Greig,et al.  Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[128]  G. Cordell,et al.  The potential of alkaloids in drug discovery , 2001, Phytotherapy research : PTR.

[129]  Tønder Je,et al.  Agonists at the a4b2 Nicotinic Acetylcholine Receptors Relationships and Molecular Modelling , 2001 .

[130]  J. Birks,et al.  Physostigmine for dementia due to Alzheimer's disease , 2001 .

[131]  K. Broadley,et al.  Muscarinic Receptor Agonists and Antagonists , 2001, Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry.

[132]  G. Hu,et al.  Similar potency of the enantiomers of huperzine A in inhibition of [3H]dizocilpine (MK-801) binding in rat cerebral cortex , 2000, Neuroscience Letters.

[133]  A. Fisher,et al.  M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives , 2000, Annals of the New York Academy of Sciences.

[134]  N. Greig,et al.  The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics , 2000, Acta neurologica Scandinavica. Supplementum.

[135]  D. Zhu,et al.  Synthesis of 5-substituted analogues of huperzine A. , 2000, Bioorganic & medicinal chemistry letters.

[136]  N. Greig,et al.  Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. , 2000, Biochemical pharmacology.

[137]  S. Sit.  Dopamine agonists in the treatment of Parkinson s disease past, present and future. , 2000, Current pharmaceutical design.

[138]  Ian D. Williams,et al.  Dimerization of an Inactive Fragment of Huperzine A Produces a Drug with Twice the Potency of the Natural Product , 2000 .

[139]  T. Chiu,et al.  Arecoline excites rat locus coeruleus neurons by activating the M2-muscarinic receptor. , 2000, The Chinese journal of physiology.

[140]  P. Camps,et al.  Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. , 2000, Molecular pharmacology.

[141]  L. Thal,et al.  Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer’s disease , 2000, Neurology.

[142]  R. Ji,et al.  Synthesis and acetylcholinesterase inhibitory activity of huperzine A-E2020 combined compound. , 1999, Bioorganic & medicinal chemistry letters.

[143]  P. Carlier,et al.  Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[144]  B. Larson,et al.  Ergocryptine and other ergot alkaloids stimulate the release of [3H]dopamine from rat striatal synaptosomes. , 1999, Journal of animal science.

[145]  N. Greig,et al.  Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. , 1999, Journal of medicinal chemistry.

[146]  L. Thal,et al.  A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease , 1999, Neurology.

[147]  Y. Shu,et al.  Recent natural products based drug development: a pharmaceutical industry perspective. , 1998, Journal of natural products.

[148]  J. Ruyun,et al.  Synthesis and acetylcholinesterase inhibitory activity of (+/-)-14-fluorohuperzine A. , 1998 .

[149]  J. Daly,et al.  6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. , 1998, Journal of medicinal chemistry.

[150]  P. Camps,et al.  Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease. , 1998, Bioorganic & medicinal chemistry.

[151]  R. Papke,et al.  Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. , 1998, The Journal of pharmacology and experimental therapeutics.

[152]  S. Kombian,et al.  Ibogaine and a Total Alkaloidal Extract of Voacanga africana Modulate Neuronal Excitability and Synaptic Transmission in the Rat Parabrachial Nucleus In Vitro , 1997, Brain Research Bulletin.

[153]  L. Teng,et al.  Nicotinic-receptor mediation of S(-)nornicotine-evoked -3H-overflow from rat striatal slices preloaded with -3H-dopamine. , 1997, The Journal of pharmacology and experimental therapeutics.

[154]  W. Kem.  Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist , 1997, Invertebrate Neuroscience.

[155]  H. Holloway,et al.  Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. , 1997, Journal of medicinal chemistry.

[156]  T. Katoh,et al.  Synthesis of (±)-12-Fluorohuperzine A, a Novel Acetylcholinesterase Inhibitor , 1997 .

[157]  I. Stolerman,et al.  Discriminative stimulus properties of the nicotinic agonist cytisine , 1997, Psychopharmacology.

[158]  P. Molnar,et al.  Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. , 1996, European journal of pharmacology.

[159]  N. Nakajima,et al.  Synthesis and acetylcholinesterase inhibitory activity of fluorinated analogues of huperzine A , 1996 .

[160]  J. Haxby,et al.  Differential Response to the Cholinergic Agonist Arecoline among Different Cognitive Modalities in Alzheimer’s Disease , 1996, Neuropsychopharmacology.

[161]  G. O'malley,et al.  Imino 1,2,3,4-tetrahydrocyclopent[b]indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase , 1996 .

[162]  L. Dwoskin,et al.  Minor alkaloids of tobacco release [3H]dopamine from superfused rat striatal slices. , 1995, European journal of pharmacology.

[163]  R. Polinsky,et al.  Effects of the cholinomimetic SDZ ENS-163 on scopolamine-induced cognitive impairment in humans. , 1995, Journal of clinical psychopharmacology.

[164]  M. Wink,et al.  Binding of quinolizidine alkaloids to nicotinic and muscarinic acetylcholine receptors. , 1994, Journal of natural products.

[165]  F. Fraunfelder,et al.  The aggravation of dementia by pilocarpine. , 1994, JAMA.

[166]  A. B. Prasad,et al.  British National Formulary , 1994 .

[167]  J. Sirviö,et al.  Cholinergic drugs regulate passive avoidance performance via the amygdala. , 1993, The Journal of pharmacology and experimental therapeutics.

[168]  B. Costall,et al.  Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset , 1992, Pharmacology Biochemistry and Behavior.

[169]  M. Duffel,et al.  Metabolism of the Catharanthus alkaloids: from Streptomyces griseus to monoamine oxidase B. , 1992, Journal of natural products.

[170]  J T O'Brien,et al.  Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. , 1991, Age and ageing.

[171]  M. Pinza,et al.  Trends in searching for new cognition enhancing drugs , 1989, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[172]  W. Evans.  Trease and Evans' Pharmacognosy , 1989 .

[173]  P. Tariot,et al.  Multiple-dose arecoline infusions in Alzheimer's disease. , 1988, Archives of general psychiatry.

[174]  R. Schwartzman,et al.  Mental status changes induced by eye drops in dementia of the Alzheimer type. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[175]  Jia-sen Liu,et al.  The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity , 1986 .

[176]  J. Wheeler,et al.  Anabaseine: venom alkaloid of aphaenogaster ants. , 1981, Science.

[177]  D. Bowen,et al.  NEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE , 1977, The Lancet.

[178]  G. Blessed,et al.  NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA , 1977, The Lancet.

[179]  R. Cichewicz,et al.  Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases. , 2011, Natural product reports.

[180]  K. G. Ramawat.  Herbal Drugs: Ethnomedicine To Modern Medicine , 2010 .

[181]  P. Houghton,et al.  Traditional Medicine for Memory Enhancement , 2009 .

[182]  A. Kunnumakkara,et al.  Mint and its constituents , 2009 .

[183]  H. Soininen,et al.  Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. , 2009, Journal of Alzheimer's disease : JAD.

[184]  K. Rangappa,et al.  Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models. , 2009, Bioorganic & medicinal chemistry.

[185]  A. Maelicke,et al.  Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy , 2009, Journal of Molecular Neuroscience.

[186]  P. Houghton,et al.  Acetylcholinesterase Inhibitors of Natural Origin , 2009 .

[187]  G. Savage,et al.  Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET , 2008, Psychopharmacology.

[188]  Rui Wang,et al.  Molecular dynamics simulations of interaction between protein-tyrosine phosphatase 1B and a bidentate inhibitor , 2006, Acta Pharmacologica Sinica.

[189]  N. Greig,et al.  Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. , 2006, Journal of Alzheimer's disease : JAD.

[190]  Dong-Yoon Lim,et al.  Arecoline inhibits catecholamine release from perfused rat adrenal gland , 2006, Acta Pharmacologica Sinica.

[191]  A. Lees.  Alternatives to Levodopa in the Initial Treatment of Early Parkinson’s Disease , 2005, Drugs & aging.

[192]  E. Levin,et al.  Acute and chronic nicotine effects on working memory in aged rats , 2005, Psychopharmacology.

[193]  C. Nicholson.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia , 2005, Psychopharmacology.

[194]  G. Small,et al.  Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease , 2003, CNS drugs.

[195]  M. Rudin,et al.  SDZ ENS 163 a novel pilocarpine like drug: pharmacological in vitro and in vivo profile. , 1993, Life sciences.

[196]  M. Duffel,et al.  Vinblastine and vincristine are inhibitors of monoamine oxidase B. , 1990, Journal of medicinal chemistry.

[197]  Yz Zhou,et al.  Study on the chemistry of huperzine-A and huperzine-B , 1986 .